Reports for APOTEX INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
25 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
367
146 (4%)
70 (29%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2019-06-05 | 2019-10-07 | 85610 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2019-06-12 | 2019-10-07 | 86336 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2019-07-03 | 2019-10-07 | 88360 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2023-07-21 | 2024-01-05 | 199518 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2023-09-28 | 2024-01-05 | 205501 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2017-03-11 | 2017-05-18 | 487 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2022-11-27 | 2023-03-09 | 175898 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2022-08-11 | 2022-10-14 | 166439 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2022-09-09 | 2022-10-14 | 169057 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2021-09-17 | 2021-11-08 | 145843 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2020-07-08 | 2020-08-21 | 119770 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2024-08-22 | 2024-11-22 | 235698 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2024-12-12 | 2025-01-24 | 245511 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2017-07-04 | 2018-01-10 | 14560 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2017-03-11 | 2017-08-18 | 504 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2018-02-05 | 2019-05-06 | 38491 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2018-11-16 | 2019-05-06 | 67031 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2025-04-04 | 2025-04-11 | 254169 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2025-01-16 | 2025-01-24 | 247859 |
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2023-06-23 | 2023-06-29 | 196303 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |
| APO-HYDROMORPHONE CR | 24MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110968 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 30MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110971 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |